search
Back to results

A Study of DS-1471a In Subjects With Advanced Solid Tumors

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
DS-1471a
Sponsored by
Daiichi Sankyo Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor focused on measuring Advanced Solid Tumor, DS-1471a

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: The clinical site will screen for the full inclusion criteria per protocol. Sign and date the informed consent form (ICF) Adults ≥18 years at the time the ICF is signed Has a histologically or cytologically documented, locally advanced, metastatic, or unresectable solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available Has at least 1 measurable lesion according to RECIST v1.1 Is willing and able to provide fresh tumor tissue biopsied at Baseline (mandatory) and on-treatment (mandatory if clinically allowed and not contraindicated) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 Life expectancy ≥3 months Has a left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to Cycle 1 Day 1 Required baseline local laboratory data (within 7 days prior to Cycle 1 Day 1) as prespecified in the protocol If the participant is a female of childbearing potential, she must have a negative serum pregnancy test within 7 days prior to study drug administration (Cycle 1 Day 1) and must be willing to use highly effective birth control upon enrollment, during the Treatment Period, and for 7 months following the last dose of study drug If male, the participant must be surgically sterile or willing to use highly effective birth control upon enrollment, during the Treatment Period, and for 4 months following the last dose of study drug Is willing and able to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions Patients with liver cirrhosis and liver cancer may be eligible to participate if they meet additional protocol specified criteria Key Exclusion Criteria: The clinical site will screen for the full exclusion criteria per protocol. Has an inadequate treatment washout period prior to start of study treatment (Cycle 1 Day 1) as prespecified in the protocol Has history of or current presence of untreated central nervous system (CNS) metastases Has a history of leptomeningeal carcinomatosis Has a history of (non-infectious) interstitial lung disease (ILD) other than radiation pneumonitis, currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening Has a history of severe pulmonary compromise or requirement of supplemental oxygen within 6 months before enrollment Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, arterial thromboembolic event, or pulmonary embolism Has uncontrolled or clinically significant cardiovascular disease Is requiring chronic steroid treatment (>10 mg daily prednisone equivalents) Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial cancer in the gastrointestinal tract curatively resected by endoscopic surgery, or any other solid tumors curatively treated with no evidence of recurrent disease for ≥3 years Has unresolved toxicities from previous anticancer treatment Exposure to another investigational medical product within 4 weeks prior to Cycle 1 Day 1 or current participation in other therapeutic investigational procedures Has an active, known, or suspected autoimmune disease Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Has an active hepatitis or uncontrolled hepatitis B or C infection, except for HCC participants with hepatitis B infection that is controlled by antiviral therapy Has human immunodeficiency virus (HIV) infection, with exceptions per protocol for participants in Dose Expansion Has received a live, attenuated vaccine (messenger RNA [mRNA] and replication-deficient adenoviral vaccines are not considered live, attenuated vaccines) within 30 days prior to first exposure to study drug (Cycle 1 Day 1) Female who is pregnant or breastfeeding or intends to become pregnant during the study Has psychological, social, familial, or geographical factors that would prevent regular follow-up Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results

Sites / Locations

  • National Cancer Center Hospital EastRecruiting
  • National Cancer Center HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Part 1, Dose Escalation Cohort 1: DS-1471a

Part 1, Dose Escalation Cohort 2: DS-1471a

Part 1, Dose Escalation Cohort 3: DS-1471a

Part 1, Dose Escalation Cohort 4: DS-1471a

Part 1, Dose Escalation Cohort 5: DS-1471a

Part 1, Dose Escalation Cohort 6: DS-1471a

Part 2, Dose Expansion (Tumor-specific Cohort 1): DS-1471a

Part 2, Dose Expansion (Tumor-specific Cohort 2): DS-1471a

Part 2, Dose Expansion (Tumor-specific Cohort 3): DS-1471a

Arm Description

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.

Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.

Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.

Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.

Outcomes

Primary Outcome Measures

Number of Participants With Dose-limiting Toxicities Following Treatment With DS-1471a (Dose Escalation)
Number of Participants With Treatment-emergent Adverse Events Following Treatment With DS-1471a (Dose Escalation and Expansion)

Secondary Outcome Measures

Best Overall Response (BOR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Best overall response (BOR) is recorded from the start of study drug until documented progressive disease (PD) or start of any anticancer treatment, whichever occurs first. Confirmation of complete response (CR) or partial response (PR) is required. As per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, CR is defined as a disappearance of all target lesions, PR is defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions).
Time to Response (TTR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Time to response (TTR) is defined as the time from the start of study drug to the date of the first documentation of response (CR or PR) as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Duration of Response (DoR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Duration of response (DoR) is defined as the time from first documentation of CR or PR to the date of the first documentation of PD as assessed by the investigator or to the date of death due to any cause, whichever occurs first. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Progression-free Survival (PFS) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Escalation and Expansion)
Progression-free survival (PFS) is defined as the time from the start date of study drug to the date of the first documentation of objective PD as assessed by the investigator or to the date of death due to any cause, whichever occurs first. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions.
Overall Survival (OS) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Escalation and Expansion)
Overall survival (OS) is defined as the time from the date of the start of study drug to the date of death due to any cause.
Objective Response Rate (ORR) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Expansion)
Confirmed objective response rate (ORR) is defined as the proportion of participants who have a confirmed BOR of CR or PR as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Disease Control Rate (DCR) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Expansion)
Disease control rate (DCR) is defined as the proportion of participants who have a BOR of CR, PR, or SD as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions, PR is defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions).
Pharmacokinetic Analysis Maximum Plasma Concentration (Cmax) of DS-1471a
Pharmacokinetic Analysis Time to Reach Maximum Plasma Concentration (Tmax) of DS-1471a
Pharmacokinetic Analysis Area Under the Plasma Concentration-Time Curve of DS-1471a
Area under the plasma concentration-time curve up to the last quantifiable time (AUClast), area under the plasma concentration-time curve from the time of dosing to 28 day (AUC28d), and area under the plasma concentration-time curve during dosing interval (AUCtau) will be assessed.
Pharmacokinetic Analysis Trough Plasma Concentration (Ctrough) of DS-1471a
Percentage of Participants With Anti-Drug Antibodies Against DS-1471a
Anti-drug antibodies (ADA) incidence is defined as the proportion of participants having treatment-emergent ADAs.

Full Information

First Posted
September 29, 2023
Last Updated
October 5, 2023
Sponsor
Daiichi Sankyo Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT06074705
Brief Title
A Study of DS-1471a In Subjects With Advanced Solid Tumors
Official Title
A Phase 1, Multicenter, First-in-human Study of DS-1471a In Subjects With Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 4, 2023 (Actual)
Primary Completion Date
June 1, 2027 (Anticipated)
Study Completion Date
June 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.
Detailed Description
The objectives of this multinational, multicenter, open-label, 2-part, dose-escalation and dose-expansion, FIH study of participants with locally advanced or metastatic solid tumors are to evaluate the safety, maximum tolerated dose (MTD), recommended dose for expansion phase, preliminary efficacy, PK, and immunogenicity of DS-1471a.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor
Keywords
Advanced Solid Tumor, DS-1471a

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1, Dose Escalation Cohort 1: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 1, Dose Escalation Cohort 2: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 1, Dose Escalation Cohort 3: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 1, Dose Escalation Cohort 4: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 1, Dose Escalation Cohort 5: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 1, Dose Escalation Cohort 6: DS-1471a
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
Arm Title
Part 2, Dose Expansion (Tumor-specific Cohort 1): DS-1471a
Arm Type
Experimental
Arm Description
Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
Arm Title
Part 2, Dose Expansion (Tumor-specific Cohort 2): DS-1471a
Arm Type
Experimental
Arm Description
Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
Arm Title
Part 2, Dose Expansion (Tumor-specific Cohort 3): DS-1471a
Arm Type
Experimental
Arm Description
Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
Intervention Type
Drug
Intervention Name(s)
DS-1471a
Intervention Description
Intravenous administration on Day 1 of each 28-day cycle
Primary Outcome Measure Information:
Title
Number of Participants With Dose-limiting Toxicities Following Treatment With DS-1471a (Dose Escalation)
Time Frame
Cycle 1: Baseline up to Day 28 (each cycle is 28 days)
Title
Number of Participants With Treatment-emergent Adverse Events Following Treatment With DS-1471a (Dose Escalation and Expansion)
Time Frame
Baseline up to 60 months
Secondary Outcome Measure Information:
Title
Best Overall Response (BOR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Description
Best overall response (BOR) is recorded from the start of study drug until documented progressive disease (PD) or start of any anticancer treatment, whichever occurs first. Confirmation of complete response (CR) or partial response (PR) is required. As per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, CR is defined as a disappearance of all target lesions, PR is defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions).
Time Frame
Baseline up to 60 months
Title
Time to Response (TTR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Description
Time to response (TTR) is defined as the time from the start of study drug to the date of the first documentation of response (CR or PR) as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Time Frame
Baseline up to 60 months
Title
Duration of Response (DoR) As Assessed by the Investigator in Participants Following Treatment With DS-1471a (Dose Escalation and Expansion)
Description
Duration of response (DoR) is defined as the time from first documentation of CR or PR to the date of the first documentation of PD as assessed by the investigator or to the date of death due to any cause, whichever occurs first. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Time Frame
Baseline up to 60 months
Title
Progression-free Survival (PFS) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Escalation and Expansion)
Description
Progression-free survival (PFS) is defined as the time from the start date of study drug to the date of the first documentation of objective PD as assessed by the investigator or to the date of death due to any cause, whichever occurs first. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions.
Time Frame
Baseline up to 60 months
Title
Overall Survival (OS) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Escalation and Expansion)
Description
Overall survival (OS) is defined as the time from the date of the start of study drug to the date of death due to any cause.
Time Frame
Baseline up to 60 months
Title
Objective Response Rate (ORR) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Expansion)
Description
Confirmed objective response rate (ORR) is defined as the proportion of participants who have a confirmed BOR of CR or PR as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
Time Frame
Baseline up to 60 months
Title
Disease Control Rate (DCR) of Participants With Advanced Solid Tumors Following Treatment With DS-1471a (Dose Expansion)
Description
Disease control rate (DCR) is defined as the proportion of participants who have a BOR of CR, PR, or SD as assessed by the investigator. As per RECIST v1.1, CR is defined as a disappearance of all target lesions, PR is defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions).
Time Frame
Baseline up to 60 months
Title
Pharmacokinetic Analysis Maximum Plasma Concentration (Cmax) of DS-1471a
Time Frame
Cycle 1 (Days 1, 2, 4, 8, 15, and 22), Cycle 2 (Day 1), Cycle 3 (Days 1, 2, 4, 8, 15, and 22), Cycles 4, 6, and 8 (Day 1), each cycle is 28 days
Title
Pharmacokinetic Analysis Time to Reach Maximum Plasma Concentration (Tmax) of DS-1471a
Time Frame
Cycle 1 (Days 1, 2, 4, 8, 15, and 22), Cycle 2 (Day 1), Cycle 3 (Days 1, 2, 4, 8, 15, and 22), Cycles 4, 6, and 8 (Day 1), each cycle is 28 days
Title
Pharmacokinetic Analysis Area Under the Plasma Concentration-Time Curve of DS-1471a
Description
Area under the plasma concentration-time curve up to the last quantifiable time (AUClast), area under the plasma concentration-time curve from the time of dosing to 28 day (AUC28d), and area under the plasma concentration-time curve during dosing interval (AUCtau) will be assessed.
Time Frame
Cycle 1 (Days 1, 2, 4, 8, 15, and 22), Cycle 2 (Day 1), Cycle 3 (Days 1, 2, 4, 8, 15, and 22), Cycles 4, 6, and 8 (Day 1), each cycle is 28 days
Title
Pharmacokinetic Analysis Trough Plasma Concentration (Ctrough) of DS-1471a
Time Frame
Cycle 1 (Days 1, 2, 4, 8, 15, and 22), Cycle 2 (Day 1), Cycle 3 (Days 1, 2, 4, 8, 15, and 22), Cycles 4, 6, and 8 (Day 1), each cycle is 28 days
Title
Percentage of Participants With Anti-Drug Antibodies Against DS-1471a
Description
Anti-drug antibodies (ADA) incidence is defined as the proportion of participants having treatment-emergent ADAs.
Time Frame
Cycle 1 (Days 1 and 8), Cycle 2 and 3 (Day 1), and Cycle 4 and every 2 cycles thereafter (Day 1), each cycle is 28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: The clinical site will screen for the full inclusion criteria per protocol. Sign and date the informed consent form (ICF) Adults ≥18 years at the time the ICF is signed Has a histologically or cytologically documented, locally advanced, metastatic, or unresectable solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available Has at least 1 measurable lesion according to RECIST v1.1 Is willing and able to provide fresh tumor tissue biopsied at Baseline (mandatory) and on-treatment (mandatory if clinically allowed and not contraindicated) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 Life expectancy ≥3 months Has a left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to Cycle 1 Day 1 Required baseline local laboratory data (within 7 days prior to Cycle 1 Day 1) as prespecified in the protocol If the participant is a female of childbearing potential, she must have a negative serum pregnancy test within 7 days prior to study drug administration (Cycle 1 Day 1) and must be willing to use highly effective birth control upon enrollment, during the Treatment Period, and for 7 months following the last dose of study drug If male, the participant must be surgically sterile or willing to use highly effective birth control upon enrollment, during the Treatment Period, and for 4 months following the last dose of study drug Is willing and able to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions Patients with liver cirrhosis and liver cancer may be eligible to participate if they meet additional protocol specified criteria Key Exclusion Criteria: The clinical site will screen for the full exclusion criteria per protocol. Has an inadequate treatment washout period prior to start of study treatment (Cycle 1 Day 1) as prespecified in the protocol Has history of or current presence of untreated central nervous system (CNS) metastases Has a history of leptomeningeal carcinomatosis Has a history of (non-infectious) interstitial lung disease (ILD) other than radiation pneumonitis, currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening Has a history of severe pulmonary compromise or requirement of supplemental oxygen within 6 months before enrollment Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, arterial thromboembolic event, or pulmonary embolism Has uncontrolled or clinically significant cardiovascular disease Is requiring chronic steroid treatment (>10 mg daily prednisone equivalents) Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial cancer in the gastrointestinal tract curatively resected by endoscopic surgery, or any other solid tumors curatively treated with no evidence of recurrent disease for ≥3 years Has unresolved toxicities from previous anticancer treatment Exposure to another investigational medical product within 4 weeks prior to Cycle 1 Day 1 or current participation in other therapeutic investigational procedures Has an active, known, or suspected autoimmune disease Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Has an active hepatitis or uncontrolled hepatitis B or C infection, except for HCC participants with hepatitis B infection that is controlled by antiviral therapy Has human immunodeficiency virus (HIV) infection, with exceptions per protocol for participants in Dose Expansion Has received a live, attenuated vaccine (messenger RNA [mRNA] and replication-deficient adenoviral vaccines are not considered live, attenuated vaccines) within 30 days prior to first exposure to study drug (Cycle 1 Day 1) Female who is pregnant or breastfeeding or intends to become pregnant during the study Has psychological, social, familial, or geographical factors that would prevent regular follow-up Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Contact for Clinical Trial Information
Phone
908-992-6400
Email
CTRinfo@dsi.com
First Name & Middle Initial & Last Name or Official Title & Degree
Japanese sites only: Daiichi Sankyo Contact for Clinical Trial Information
Phone
+81-3-6225-1111(M-F 9-5 JST)
Email
dsclinicaltrial@daiichisankyo.co.jp
Facility Information:
Facility Name
National Cancer Center Hospital East
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
See Central Contact
Facility Name
National Cancer Center Hospital
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
See Central Contact

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing URL
https://vivli.org/ourmember/daiichi-sankyo/

Learn more about this trial

A Study of DS-1471a In Subjects With Advanced Solid Tumors

We'll reach out to this number within 24 hrs